The estimated Net Worth of Armen Shanafelt is at least $1.89 Milión dollars as of 9 December 2021. Armen Shanafelt owns over 150,000 units of Aeglea BioTherapeutics Inc stock worth over $1,801,500 and over the last 9 years he sold AGLE stock worth over $0. In addition, he makes $91,944 as Independent Director at Aeglea BioTherapeutics Inc.
Sign up
Armen Shanafelt AGLE stock SEC Form 4 insiders trading
Armen has made over 4 trades of the Aeglea BioTherapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 150,000 units of AGLE stock worth $549,000 on 9 December 2021.
The largest trade he's ever made was buying 583,333 units of Aeglea BioTherapeutics Inc stock on 16 August 2016 worth over $6,999,996. On average, Armen trades about 56,788 units every 88 days since 2016. As of 9 December 2021 he still owns at least 150,000 units of Aeglea BioTherapeutics Inc stock.
You can see the complete history of Armen Shanafelt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Armen Shanafelt biography
Dr. Armen B. Shanafelt Ph.D. serves as Independent Director of the Company. Dr. Shanafelt has served as venture partner, then general partner, of Lilly Ventures, a venture capital firm. Prior to joining Lilly Ventures, Dr. Shanafelt was one of several Chief Science Officers at Eli Lilly and Company, a pharmaceutical research company, specifically responsible for the generation of the early biotherapeutic pipeline which spanned the therapeutic areas of oncology, endocrine and neuroscience. Dr. Shanafelt also serves on the board of directors of Surface Oncology, Inc. Dr. Shanafelt previously served on the boards of directors of Aileron Therapeutics, Inc., Protagonist Therapeutics, Inc., Sutro Biopharma, Inc., and Symic Bio. Dr. Shanafelt received his B.S. in Chemistry and Physics from Pacific Lutheran University and his Ph.D. in Chemistry from the University of California, Berkeley. He completed his postdoctoral work at DNAX Research Institute. He is a Kauffman Fellow (Class 14). Shanafelt is qualified to serve on our board of directors because of his experience in the pharmaceutical and biotechnology businesses, including his expertise with respect to the generation of early biotherapeutic pipelines and his investment and board experience while a partner with Lilly Ventures.
What is the salary of Armen Shanafelt?
As the Independent Director of Aeglea BioTherapeutics Inc, the total compensation of Armen Shanafelt at Aeglea BioTherapeutics Inc is $91,944. There are 10 executives at Aeglea BioTherapeutics Inc getting paid more, with Anthony Quinn having the highest compensation of $2,482,780.
How old is Armen Shanafelt?
Armen Shanafelt is 60, he's been the Independent Director of Aeglea BioTherapeutics Inc since 2019. There are 1 older and 14 younger executives at Aeglea BioTherapeutics Inc. The oldest executive at Aeglea BioTherapeutics Inc is V. Bryan Lawlis, 68, who is the Independent Director.
What's Armen Shanafelt's mailing address?
Armen's mailing address filed with the SEC is 115 W Washington St #1680-South, Indianapolis, IN 46204, USA.
Insiders trading at Aeglea BioTherapeutics Inc
Over the last 9 years, insiders at Aeglea BioTherapeutics Inc have traded over $1,425,674 worth of Aeglea BioTherapeutics Inc stock and bought 1,931,829 units worth $12,152,489 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bioventures Ltd Novartis Ag... a Advisors Llc Orbi Med Capit.... On average, Aeglea BioTherapeutics Inc executives and independent directors trade stock every 70 days with the average trade being worth of $864,564. The most recent stock trade was executed by Marcio Souza on 25 August 2022, trading 90,000 units of AGLE stock currently worth $50,400.
What does Aeglea BioTherapeutics Inc do?
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
What does Aeglea BioTherapeutics Inc's logo look like?
Complete history of Armen Shanafelt stock trades at Aeglea BioTherapeutics Inc, Protagonist Therapeutics Inc, Aileron Therapeutics Inc a Surface Oncology Inc
Aeglea BioTherapeutics Inc executives and stock owners
Aeglea BioTherapeutics Inc executives and other stock owners filed with the SEC include:
-
Anthony Quinn,
President and Chief Executive Officer, Director -
Leslie Sloan,
Chief Operating Officer -
Charles York,
Chief Financial Officer, Vice President -
Dr. Anthony G. Quinn M.D., M.B Ch.B., Ph.D., FRCP,
Pres, CEO & Director -
Dr. Leslie S. Sloan Ph.D.,
Chief Operating Officer -
Russell Cox,
Independent Chairman of the board -
Sandesh Mahatme,
Independent Director -
Suzanne Bruhn,
Independent Director -
Ivana Magovcevic-Liebisch,
Independent Director -
V. Bryan Lawlis,
Independent Director -
Armen Shanafelt,
Independent Director -
Joey Perrone,
Director, Finance & Investor Relations -
Ravi Rao,
Chief Medical Officer -
Michael Hanley,
Chief Commercial Officer -
Michael C. Hanley M.B.A.,
Chief Commercial Officer -
Eugene Sackett,
VP of HR -
Kelly Boothe Ph.D.,
Sr. Director of Corp. Communications -
James Paul Kastenmayer J.D., Ph.D.,
Gen. Counsel -
Cortney Caudill M.B.A.,
Sr. VP of Technical Operations -
Steven Weber,
VP, Principal Accounting Officer & Corp. Controller -
Jonathan D. Alspaugh M.B.A.,
Chief Financial Officer -
Aaron Schuchart,
Chief Business Officer -
Joseph E Tyler,
VP, Manufacturing -
Scott W Rowlinson,
VP, Research -
David George Lowe,
CEO and President -
Henry Hebel,
VP, Product Development -
Advisors Llc Orbi Med Capit...,
-
George Georgiou,
Director -
Lilly & Co Eli,
10% owner -
Bioventures Ltd Novartis Ag...,
-
Laurie Stelzer,
-
Jeffrey W. Albers,
-
Cameron Turtle,
Chief Executive Officer -
Funds Management Llc Fairmo...,
-
Heidy King Jones,
See Remarks -
Scott L Burrows,
Chief Financial Officer -
James Wooldridge,
Chief Medical Officer -
Linda L Neuman,
Chief Medical Officer -
Alison Frances Lawton,
Director -
Marcio Souza,
Director -
Steven Weber,
VP, Controller&Princ Acctg Off -
Bros. Advisors Lp667, L.P.B...,
-
Hunter C Smith,
Director -
James Paul Kastenmayer,
General Counsel -
Jeff Marc Goldberg,
President and CEO -
Jonathan Alspaugh,
President and CFO